IMDNA provides scientific, technical, and non-regulatory support for development of point-of-care (POC), point-of-need, and lateral flow assay (LFA) technologies for research, product-development, and translational applications. Programs may involve antigen detection, antibody detection, protein biomarkers, small-molecule/hapten formats, nucleic-acid–coupled readouts, qualitative or semi-quantitative lateral flow, reader-assisted systems, and multiplex concepts where scientifically appropriate.
A successful lateral flow test depends on much more than the recognition reagent. Sample behavior, membrane flow, binding kinetics, reporter chemistry, conjugate release, capture-line architecture, background, signal stability, reader design, user steps, packaging, storage, manufacturability, and interpretation all interact. IMDNA therefore treats POC/LFA development as an integrated product-development system rather than as a single strip-optimization experiment.
WHO target-product-profile frameworks emphasize that point-of-care tests should be developed around intended users, operating environment, sample needs, turnaround time, storage, transport, waste handling, interpretation, and product labeling. The assay architecture should therefore follow the real-world use case rather than forcing a laboratory method into a portable format after development is complete.
Define whether the concept is intended for trained laboratory personnel, healthcare professionals, field users, research personnel, or another user group.
Consider laboratory-adjacent, clinic, office, field, decentralized, home-use research, veterinary, environmental, or other relevant settings.
Define sample type, collection burden, pretreatment needs, transfer steps, reaction time, interpretation, and disposal before finalizing strip design.
Translate the intended use into measurable development goals for analytical performance, turnaround, storage, packaging, usability, manufacturing, and cost.
Published reviews describe LFAs as capillary-driven paper/membrane systems in which sample, labeled recognition reagents, capture reagents, and absorbent components work together to generate a visible or instrument-read signal. Changes in one component can influence flow rate, binding time, background, signal intensity, and assay sensitivity across the whole strip.
Controls sample entry, filtration, release, volume handling, buffering, and compatibility with downstream membrane flow.
Stores and releases labeled recognition reagents while preserving stability, rapid rehydration, and effective analyte binding.
Provides the capillary-flow environment where analyte complexes encounter test and control capture zones.
Contains target-specific capture chemistry selected to generate an interpretable signal when the intended analyte is present.
Provides evidence that key fluidic and reagent-release steps occurred, subject to the assay design.
Maintains capillary flow and fluid capacity through the intended read window.
Supports alignment, handling, protection, readability, sample application, and integration into a cassette or other device format.
Can provide objective signal capture, semi-quantitative analysis, result archiving, connectivity, or algorithmic interpretation where appropriate.
IMDNA can support development from biological feasibility through analytical characterization, product engineering, and transfer readiness.
| Format | Typical Molecular Logic | Development Considerations |
|---|---|---|
| Sandwich LFA | Target analyte is bound by a labeled recognition reagent and a second immobilized capture reagent. | Best suited when two compatible binding events are possible; requires epitope accessibility, pair compatibility, signal window, specificity, and hook-effect assessment. |
| Competitive LFA | Signal changes as sample analyte competes with an immobilized or labeled analog. | Useful for small analytes or targets that cannot readily support a two-site sandwich; result direction and user interpretation require careful design. |
| Antibody-Detection LFA | Detects analyte-specific antibodies using antigen/reagent capture systems. | Requires careful control of nonspecific binding, immunoglobulin class, matrix effects, cross-reactivity, and timing of biological antibody response. |
| Nucleic-Acid–Coupled LFA | LFA functions as the downstream visual/digital readout of a separate amplification or recognition reaction. | Requires integration of upstream amplification chemistry, contamination control, product capture, workflow complexity, and user steps. |
| Multiplex LFA | Uses multiple test zones, labels, or reader-assisted discrimination to detect more than one target. | Limited by strip geometry, flow, reagent interactions, line discrimination, signal competition, sample volume, and interpretation complexity. |
Modern lateral-flow platforms can use antibodies, recombinant binders, nanobodies, aptamers, oligonucleotide recognition systems, or other target-specific binding elements, depending on assay chemistry. Signal labels may include traditional colorimetric particles or reader-assisted optical reporters. The appropriate combination depends on target abundance, required sensitivity, stability, manufacturability, and user-readout needs.
Evaluate specificity, affinity, epitope compatibility, cross-reactivity, matrix behavior, and stability in the complete strip environment.
Nanobodies, aptamers, or other engineered recognition reagents may be considered where they provide technical advantages and suitable evidence.
Visible particulate reporters can support simple instrument-free interpretation but require adequate signal-to-background and environmental stability.
Can expand sensitivity and enable objective or semi-quantitative interpretation, while adding reader, calibration, software, and usability requirements.
Enzymatic, nanoparticle, or other amplification approaches may increase sensitivity but can also add steps, time, instability, or manufacturing complexity.
Reporter and assay architecture should be selected around expected analyte levels and the clinically or scientifically meaningful performance range.
Reviews of POC diagnostic development repeatedly identify sample preparation as a major barrier to practical deployment. Complex matrices can change viscosity, flow, nonspecific binding, analyte accessibility, particle aggregation, background, and signal. A low-complexity strip cannot compensate for a poorly defined sample interface.
Cellular content, hematocrit, viscosity, hemoglobin, filtration, and sample volume can materially affect flow and visual interpretation.
Protein composition, anticoagulant, viscosity, matrix interference, and analyte stability should be considered.
Variable viscosity, mucins, pH, collection method, food/drink effects, and target abundance can influence performance.
Collection device, extraction buffer, mucus, transport conditions, and target release can affect reproducibility.
pH, ionic strength, dilution, particulates, and concentration variability may alter binding and membrane flow.
Matrix composition can be highly variable and may require project-specific sample-conditioning strategies.
The analytical evaluation package should be matched to the intended use and product-development stage. A strong LFA program examines not only whether a line appears, but whether the assay remains consistent across target levels, sample matrices, lots, operators, storage conditions, and realistic sources of interference.
Characterize low-level performance using replicate studies and predefined criteria appropriate to the qualitative, semi-quantitative, or quantitative claim.
Evaluate cross-reactivity with related targets and interference from relevant endogenous/exogenous substances.
Assess consistency across operators, days, lots, devices, readers, sites, or environmental conditions where appropriate.
For sandwich formats, challenge sufficiently high analyte concentrations to determine whether antigen excess reduces test-line signal.
Evaluate whether sample types or collection methods intended to be interchangeable actually produce comparable behavior.
Define the period during which signal should be interpreted and determine whether early or delayed reading changes results.
Where both visual and instrument-assisted interpretation are planned, assess how the two approaches compare and define the primary interpretation method.
Challenge realistic changes in sample volume, timing, temperature, humidity, handling, manufacturing lot, and other use conditions.
Point-of-care performance depends on both analytical chemistry and human interaction. The number of user steps, sample-transfer precision, timing burden, interpretation rules, labeling, control-line logic, device ergonomics, and environmental conditions can all influence real-world performance. For products intended for waived or home-use pathways, usability and risk control become especially important and require formal product-specific evaluation by the responsible manufacturer and regulatory team.
FDA categorizes IVD tests under CLIA as waived, moderate complexity, or high complexity. Tests cleared or approved for home use are automatically categorized as waived, while other tests may require a separate CLIA Waiver by Application after clearance/approval. This means that “point-of-care” and “CLIA-waived” are not interchangeable terms. IMDNA can support technical simplification and usability-informed design, but FDA determines CLIA categorization and waiver status.
Reduce unnecessary transfers, timing decisions, mixing steps, calculations, and opportunities for procedural error where scientifically feasible.
Design the device and instructions so the intended sample amount, location, buffer sequence, and read time are easy to understand.
Ensure the control mechanism provides meaningful evidence of assay flow or reagent functionality appropriate to the design.
Use unambiguous visual or reader-based interpretation and clearly define invalid, negative, positive, or semi-quantitative result categories where appropriate.
Consider temperature, humidity, lighting, transport, handling, and other conditions relevant to the intended use environment.
Use iterative user feedback and formal human-factors/usability processes when required by the product's intended use and regulatory pathway.
Instrument-free visual readout preserves simplicity and portability, but very faint lines can introduce subjectivity. The assay should be designed so expected positive and negative states can be interpreted reliably within the specified read window.
Published LFA literature describes reader and smartphone approaches for objective imaging, semi-quantitative analysis, connectivity, and data storage. These systems can reduce visual subjectivity but add calibration, software, device compatibility, cybersecurity/data, algorithm, and usability considerations.
Published reviews note that multiplex LFAs can expand information from one sample but are constrained by strip geometry, membrane flow, reagent competition, line spacing, limited sample volume, cross-reactivity, and interpretation. Multiplexing should therefore be driven by a meaningful use case and validated target by target.
Provides straightforward spatial discrimination but increases competition for sample, conjugate, and membrane area.
Different colors or optical signatures can increase multiplex capability but require signal separation and reader/visual validation.
When one strip becomes too complex, dividing targets across complementary devices may produce more robust performance.
High-abundance targets or high-affinity interactions can influence delivery of reagents and analyte to downstream zones.
More lines increase user and algorithmic interpretation burden and require clear invalid/positive/negative rules.
Each target requires its own specificity, sensitivity, interference, and performance evaluation even when the final product is multiplexed.
A prototype that works immediately after assembly is not yet a robust POC product. Reporter particles, biological binders, membranes, pads, adhesives, buffers, desiccants, pouches, cassettes, and printed labels can all influence long-term performance and manufacturing consistency.
Evaluate whether recognition reagents and reporters retain function under intended storage and in-use conditions.
Membranes, conjugates, and dried reagents can be moisture sensitive; packaging strategy should reflect this risk.
Support pouch, desiccant, cassette, buffer, accessories, labeling, and kit organization appropriate to the use case.
Define component traceability, incoming material checks, in-process controls, and lot-specific functional QC.
Review how dispensing, drying, lamination, cutting, assembly, and packaging changes may affect signal or flow as production increases.
Transfer product drawings, BOMs, critical materials, process parameters, QC methods, acceptance criteria, and troubleshooting knowledge.
Plan distribution conditions around evidence for temperature, humidity, handling, and packaging protection.
Evaluate changes in membrane, antibodies, particles, pads, adhesives, packaging, readers, or suppliers for possible impact on performance.
Define target, use case, sample, test format, readout, desired performance, user environment, and technical-development risks.
Support antibody-pair evaluation and assessment of other target-specific binders where scientifically appropriate.
Support component selection, fluidic concept, capture-zone design, cassette format, sample interface, and reader integration at the product-development level.
Evaluate visual or instrument-assisted reporter strategies based on required sensitivity, stability, user workflow, and manufacturing complexity.
Evaluate sample compatibility, buffering, flow behavior, background, target accessibility, and practical pretreatment needs.
Detection capability, specificity, interference, reproducibility, hook-effect risk, matrix equivalence, read window, robustness, and comparator studies.
Support BOMs, component traceability, lot QC, packaging, stability, scale-up, troubleshooting, and technical documentation.
Support product documentation, technical transfer, validation-support materials, OEM/private-label transition, and coordination with the product owner's regulatory/quality team.
IMDNA provides scientific, technical, product-development, assay-development, analytical-evaluation, manufacturing-readiness, documentation, troubleshooting, and non-regulatory support for point-of-care and lateral flow technologies. Support may include target and use-case definition, recognition-reagent evaluation, assay-format selection, strip/device architecture, sample/matrix assessment, reporter strategy, reader integration, analytical study design, lot QC, stability/packaging support, scale-up, technology transfer, and commercialization documentation.
Point-of-care does not automatically mean CLIA-waived, FDA-cleared, FDA-approved, home-use authorized, or otherwise regulatorily authorized. In the United States, FDA categorizes applicable IVD tests under CLIA as waived, moderate complexity, or high complexity, and certain products may require a separate CLIA Waiver by Application. Regulatory status depends on the specific product, intended use, user, setting, claims, and evidence.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, governmental, or inspecting authority. IMDNA does not determine final CLIA categorization, authorize home use, grant a waiver, approve labeling, or grant market authorization.
The responsible product owner, sponsor, applicant, laboratory, or manufacturer remains responsible for determining the applicable regulatory pathway; approving intended use and claims; planning formal usability, clinical, analytical, manufacturing, and quality-system evidence; submitting to authorities; and obtaining any required clearance, approval, waiver, registration, listing, licensing, certification, or authorization.
References to FDA, WHO, NIH/NCBI, or published literature are provided for scientific and informational context only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA.
The following sources support the scientific and product-development framework used on this page. Their formal applicability depends on product type, intended use, regulatory pathway, user, setting, and jurisdiction.
Tell IMDNA about your target analyte, intended sample, assay concept, target user, desired turnaround, visual or reader-assisted format, expected target range, sample-preparation needs, multiplex goals, storage conditions, production scale, and research or commercialization objective. Our scientific and technical team can help structure a POC/LFA development program covering feasibility, assay architecture, matrix compatibility, analytical evaluation, usability-informed design, packaging, lot QC, scale-up, documentation, and technology transfer.